Akero Therapeutics
AKRO
AKRO was delisted on the 8th of December, 2025.
265 hedge funds and large institutions have $4.34B invested in Akero Therapeutics in 2025 Q3 according to their latest regulatory filings, with 46 funds opening new positions, 75 increasing their positions, 92 reducing their positions, and 36 closing their positions.
221% more call options, than puts
Call options by funds: $52.4M | Put options by funds: $16.3M
28% more first-time investments, than exits
New positions opened: 46 | Existing positions closed: 36
3% more funds holding
Funds holding: 257 → 265 (+8)
1.25% less ownership
Funds ownership: 115.58% → 114.34% (-1.2%)
12% less capital invested
Capital invested by funds: $4.92B → $4.34B (-$574M)
18% less repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 92
31% less funds holding in top 10
Funds holding in top 10: 16 → 11 (-5)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$51.3M |
| 2 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$46.4M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$40.8M |
| 4 |
State Street
Boston,
Massachusetts
|
+$32.4M |
| 5 |
American Century Companies
Kansas City,
Missouri
|
+$32.1M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$88.5M |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$82M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$50.7M |
| 4 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$33.9M |
| 5 |
EC
EcoR1 Capital
San Francisco,
California
|
-$23.5M |
AKRO Hedge Fund Activity: Q3 2025 in Review
265 of the 7,640 institutional investors tracked by Wall St. Rank reported a position in Akero Therapeutics (AKRO) for Q3 2025, worth a combined $4.34B — down 12% from $4.92B a quarter earlier.
Buyers outnumbered sellers: 46 funds opened new AKRO positions and 36 closed out — a net gain of 10 holders — while 75 added to existing stakes and 92 trimmed.
The largest buyer was Polar Capital Holdings, opening a new position worth an estimated $51.3M. The largest seller was Woodline Partners, cutting an estimated $88.5M.
- 265 institutional investors held Akero Therapeutics (AKRO) as of Q3 2025, up from 257 in Q2 2025.
- Funds reported $4.34B of Akero Therapeutics stock for Q3 2025, down 12% quarter-over-quarter.
- 46 funds opened new Akero Therapeutics positions in Q3 2025 and 36 closed out, a net change of +10 holders.
- The largest Akero Therapeutics buyer in Q3 2025 was Polar Capital Holdings, an estimated $51.3M added.
- The largest Akero Therapeutics seller in Q3 2025 was Woodline Partners, an estimated $88.5M sold.
Based on aggregated 13F filings for Q3 2025.